Trial Profile

A Phase II, Single-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Measles, Mumps, Rubella, Varicella Vaccine Compared With ProQuad, Administered in Healthy Children 4-6 Years of Age

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MMR-varicella zoster virus vaccine (Primary)
Indications Chickenpox; Measles; Mumps; Rubella; Varicella zoster virus infections
Focus Pharmacodynamics
Sponsors GlaxoSmithKline; GSK

07 Feb 2025 Status changed from active, no longer recruiting to completed.
03 May 2024 Planned End Date changed from 17 Jun 2024 to 15 Oct 2024.
03 May 2024 Planned primary completion date changed from 31 Jan 2024 to 4 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com